West reports third-quarter 2025 results

- delivered solid growth across proprietary products and contract manufacturing segments -  - achieved double-digit growth in hvp components - - strengthened executive leadership team, including recently appointed cfo robert mcmahon - - increases full-year 2025 revenue and eps guidance - exton, pa. , oct. 23, 2025 /prnewswire/ -- west pharmaceutical services, inc. (nyse: wst), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2025.
WST Ratings Summary
WST Quant Ranking